Mallinckrodt/Epix MS-325 vascular MRI imaging agent nearing Phase II -- Epix offering prospectus.
Executive Summary
EPIX MEDICAL MS-325 VASCULAR IMAGING AGENT PHASE II TRIALS will test the agent's ability to enhance magnetic resonance imaging of arteries and veins as an alternative to X-ray angiography, Epix Medical said in a recent initial public offering prospectus. The company believes that MS-325 may have applications in diagnosis of coronary artery disease, peripheral vascular disease and thrombosis. Epix is developing MS-325 in collaboration with Mallinckrodt.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth